Navigation Links
Proof of Concept Study Initial Findings
Date:1/28/2013

PERTH, Australia, Jan. 28, 2013 /PRNewswire/ -- Bone Medical Ltd (ASX: BNE), a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

These first results confirm that BN006 reduces inflammation in a collagen-antibody induced arthritis disease model, a widely used benchmark for evaluating and comparing novel treatments for RA. The reduction appeared to be dose-related.

Significantly, BN006 achieved notable reduction in inflammation with only a modest reduction of TNF. TNF is one of the body's inflammatory agents that play an important role in the RA disease process.  BN006 has also been shown to reduce IL-6, another cytokine involved in RA.

Dr Roger New , CSO and inventor of the Mozaic™ system, explained, "The current standard of care for the treatment of RA works by binding to TNF and blocking its activity systemically.  This approach reduces TNF's ability to play its role in the body's immune response, leading to the adverse events that most commonly limit the clinical role of these products."

"In our study, BN006 achieved its effect with only a small reduction in TNF," continued Dr New. "While adalimumab (Humira™) eliminated inflammation in our study, it almost completely blocked TNF.  This provides experimental evidence for BN006's selective mechanism of action, which acts directly on macrophages to reduce their inflammatory activity, and confirms its potential to become an important advance in the treatment for RA."

Dr New said the Company was continuing to evaluate the results of the study, and would add another BN006 treatment arm to further expand the study outcomes.  More complete results are expected over the next couple of months.Contact:Dr Roger NewPeter YoungChairmanCEO+44 207 794 1512

+1 201 841 9681Leon IvoryDirector+61 419 428 264

or visit: www.bone-ltd.comAbout Bone Medical LimitedBone Medical Limited focuses on developing significant new products for the treatment of bone diseases like osteoarthritis, rheumatoid arthritis, and osteoporosis.  The Company's product pipeline includes Phase II clinical-stage programs for the oral delivery of CaPTHymone™ (parathyroid hormone) for osteoporosis and Capsitonin™ (calcitonin) for osteoarthritis pain and osteoporosis, and novel preclinical-stage compounds like BN006, BN007, a collagen tolerance & joint protection agent for RA, and BN005 & BN008, bone cell regulators for osteoporosis.

 


'/>"/>
SOURCE Bone Medical Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
2. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
3. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
4. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
5. A New Audio Interview With Ronald Adams President Of Medical Alarm Concepts Holding, Inc., Is Now At SmallCapVoice.com
6. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
7. Medical Alarm Concepts Publishers Shareholder Letter
8. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
9. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
10. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
11. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):